RxDoctor Payments Data

Haiyan Liu

Clinical Nurse Specialist · Austin, TXNPI 1144481003

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $955 and has fallen 54.7% since, to $433 in 2025.

$1,651in general payments, 2019–2025

Across 17 payments — averaging $97.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$376
  • Teleflex LLC$167
  • Biotronik NRO, Inc.$146
  • Amgen$140
  • AstraZeneca$122
  • Abbott$119
  • plus $581 from 8 others

What the payments were for

  • Food & beverage$1,651100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,651 in reported general payments places this provider in the 80th percentile of 88 clinical nurse specialist providers in Texas.

See all clinical nurse specialist providers in Texas

Medicare billing

Part B allowed, 2024
$156,974
Medicare patients
113
Services billed
1,743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnbrelEtanercept12$95,414
EliquisApixaban222$65,639
MyrbetriqMirabegron56$15,446
XareltoRivaroxaban35$9,988
RestasisCyclosporine17$9,405
AptiomEslicarbazepine Acetate14$8,885
LinzessLinaclotide13$7,516
JanuviaSitagliptin Phosphate24$6,903
Pantoprazole Sodium45$5,878
CombiganBrimonidine Tartrate/Timolol12$5,297
Sucralfate15$5,022
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$4,637
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$4,390
Enoxaparin Sodium12$4,378
VascepaIcosapent Ethyl24$4,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$140$95,41412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 88 clinical nurse specialist providers in Texas.

Other clinical nurse specialist in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →